< Back to previous page
Researcher
Johan Vansteenkiste
- Disciplines:Respiratory medicine
Affiliations
- Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE) (Division)
Member
From1 Oct 1999 → 30 Sep 2022
Projects
1 - 3 of 3
- Refining the role of dual checkpoint inhibition in advanced lung cancer: a single-cell approachFrom5 Oct 2021 → TodayFunding: FWO Strategic Basic Research Grant
- A single-cell approach to identify biomarkers of efficacy and toxicity for immune checkpoint blockade in non-small cell lung cancer.From1 Aug 2019 → 1 Aug 2023Funding: FWO Strategic Basic Research Grant, Foundations, funds and other with scientific goal
- Unraveling the common genetic basis for COPD, emphysema and lung cancer.From1 Aug 2010 → 16 Dec 2015Funding: Private funding of national origin - undefined, FWO fellowships
Publications
41 - 50 of 278
- An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates(2020)
Authors: Katerina Rohlenova, Federico Taverna, Lucas Treps, Vincent Geldhof, Laura De Rooij, Liliana Sokol, Junbin Qian, Laure-Anne Teuwen, Bram Boeckx, Els Wauters, et al.
Pages: 21 - + - Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC(2020)
Authors: Ingrid Demedts, Johan Vansteenkiste
Pages: 41 - 50 - Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA(2020)
Authors: Johan Vansteenkiste
Pages: 138 - 143 - Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial(2020)
Authors: Johan Vansteenkiste
Pages: 94 - 103 - Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion(2019)
Authors: Christophe Dooms, Johan Vansteenkiste
Pages: 28 - 35 - Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report(2019)
Authors: Johan Vansteenkiste, Christophe Dooms
Pages: 2109 - 2119 - Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer(2019)
Authors: Johan Vansteenkiste
Pages: 6644 - 6652 - CAPMATINIB (INC280) IN MET Delta EX14-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY DATA FROM THE PHASE 2 GEOMETRY MONO-1 STUDY(2019)
Authors: Rebecca S Heist, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry JM Groen, Daniel SW Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov, et al.
Pages: 56 - 56 - A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer(2019)
Authors: Johan Vansteenkiste
Pages: 136 - 143 - Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration(2019)
Authors: Johan Vansteenkiste
Pages: 1686 - 1688